CLINICAL TRIALS PROFILE FOR CILTACABTAGENE AUTOLEUCEL

All Clinical Trials for ciltacabtagene autoleucel

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04181827 ↗	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalid	Recruiting	Janssen Research & Development, LLC	Phase 3	2020-06-12	The purpose of this study is to compare the efficacy of JNJ-68284528 (ciltacabtagene autoleucel [cilta-cel]) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
NCT04923893 ↗	A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Who	Recruiting	Janssen Research & Development, LLC	Phase 3	2021-08-19	The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).
NCT05201781 ↗	A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel	Not yet recruiting	Janssen Research & Development, LLC	Phase 4	2022-01-21	The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
NCT05257083 ↗	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants	Not yet recruiting	Janssen Research & Development, LLC	Phase 3	2022-06-01	The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
NCT05257083 ↗	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants	Not yet recruiting	European Myeloma Network	Phase 3	2022-06-01	The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

Clinical Trial Conditions for ciltacabtagene autoleucel

Condition Name

Condition Name for ciltacabtagene autoleucel
Intervention	Trials
Multiple Myeloma	11
Refractory Multiple Myeloma	2
High Risk Smoldering Multiple Myeloma	1
Myeloma	1

Condition MeSH

Condition MeSH for ciltacabtagene autoleucel
Intervention	Trials
Multiple Myeloma	13
Neoplasms, Plasma Cell	7
Renal Insufficiency	1
Smoldering Multiple Myeloma	1

Clinical Trial Locations for ciltacabtagene autoleucel

Trials by Country

Trials by Country for ciltacabtagene autoleucel
Location	Trials
United States	76
Spain	6
Australia	5
Germany	4
Netherlands	3

Trials by US State

Trials by US State for ciltacabtagene autoleucel
Location	Trials
New York	6
Wisconsin	6
North Carolina	5
Minnesota	5
Michigan	5

Clinical Trial Progress for ciltacabtagene autoleucel

Clinical Trial Phase

Clinical Trial Phase for ciltacabtagene autoleucel
Clinical Trial Phase	Trials
PHASE2	6
PHASE1	2
Phase 4	1

Clinical Trial Status

Clinical Trial Status for ciltacabtagene autoleucel
Clinical Trial Phase	Trials
RECRUITING	10
Not yet recruiting	4
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for ciltacabtagene autoleucel

Sponsor Name

Sponsor Name for ciltacabtagene autoleucel
Sponsor	Trials
Janssen Research & Development, LLC	8
Washington University School of Medicine	2
PETHEMA Foundation	1

Sponsor Type

Sponsor Type for ciltacabtagene autoleucel
Sponsor	Trials
Other	11
Industry	10
NIH	1

Ciltacabtagene Autoleucel (Carvykti): Clinical Trials, Market Analysis, and Future Projections

Last updated: February 27, 2026

What is the clinical development status of ciltacabtagene autoleucel?

Ciltacabtagene autoleucel (Carvykti) received FDA approval in February 2022 for relapsed or refractory multiple myeloma (RRMM) after at least four prior lines of therapy. The drug is a B-cell maturation antigen (BCMA)-directed, chimeric antigen receptor T-cell (CAR-T) therapy developed by Janssen/Legend Biotech.

Current clinical trials include:

• Phase 3 CARTITUDE-4: comparing Carvykti with standard therapies.
• Phase 2 CARTITUDE-5: evaluating earlier lines of treatment.
• Ongoing trials in Europe and Asia for broader indications.

The pivotal trial, CARTITUDE-1, showed an overall response rate (ORR) of 98% with a complete response (CR) rate of 78% in heavily pretreated patients, with a median duration of response (DOR) of 21.8 months at data cutoff.

How does the drug perform statistically in clinical trials?

Metric	CARTITUDE-1 Data (N=113)	FDA Filing Data	Comments
Overall Response Rate (ORR)	98%	100%	All patients had at least a partial response
Complete Response (CR)	78%	70-75%	High CR rate for heavily pretreated patients
Minimal Residual Disease (MRD) negativity	67%	Not specified	MRD negativity assessed at 10^-5 sensitivity
Median DOR	21.8 months	Not specified	Response durability suggests durable remissions

Janssen reports an overall manageable safety profile, with adverse events including cytokine release syndrome (CRS) in 84% (Grade 1-2), and neurotoxicity in 18%. Severe CRS (Grade 3-4) occurs in roughly 4%.

What is the current market landscape for CAR-T therapies in multiple myeloma?

Market size and competition

The multiple myeloma (MM) CAR-T market is emerging, with several players.

Product	Developer	Approval Status	Indication	Key Data
Carvykti (Ciltacabtagene autoleucel)	Janssen/Legend Biotech	Approved (2022)	Relapsed/refractory MM	ORR 98% in trials
Abecma (Idecabtagene vicleucel)	Bristol-Myers Squibb	Approved (2021)	R/r MM	ORR 73%, median DOR 10.9 months
Ascent + Targeted Therapies	Under Trial	Ongoing	Earlier lines of MM	Expected to expand market reach

Market penetration estimates

• Estimated global multiple myeloma market was valued at $23 billion in 2022.
• CAR-T therapies account for roughly 10-15% of this, projected to reach 25% by 2030 due to increasing approvals.
• Carvykti's high efficacy and manageable safety profile give it a competitive advantage, particularly in heavily pretreated patients.

Pricing and reimbursement

• Approved price: approximately $410,000 per treatment course.
• Reimbursement landscape remains complex, with payers increasingly willing to cover CAR-T for approved indications.
• Reimbursement policies vary by country; in the U.S., CMS considers coverage based on the latest clinical data and FDA approval.

What are the projections for market growth and future adoption?

Growth forecast

Year	Estimated Market Share	Total Sales (USD billion)	Assumptions
2022	15%	$3.45	Initial adoption, primarily in third-line MM
2025	22%	$6.7	Expansion into earlier lines, increased clinical confidence
2030	30%	$10.0	Broader indications, combination therapies, price stabilization

• Market expansion driven by:

• Evidence supporting use in earlier lines (e.g., CARTITUDE-5).
• Growing acceptance of CAR-T therapies as standard care for RRMM.
• Pipeline developments introducing next-generation constructs with improved safety and efficacy.

Risks impacting projections

• Manufacturing delays or bottlenecks.
• Safety concerns or adverse events limiting use.
• Regulatory barriers for expanded indications.
• Competition from other BCMA-targeted therapies and bispecifics.

Key takeaways

• FDA approval in 2022 positions Carvykti as a leading CAR-T therapy for multiple myeloma.
• Clinical trials demonstrate high response rates with durable remissions in heavily pretreated populations.
• The market is expanding from niche refractory cases into earlier treatment lines.
• Global adoption hinges on reimbursement, manufacturing capacity, and clinical acceptance.
• Growth projections highlight potential for substantial market share increases through pipeline development and broader indications.

5 FAQs

Q1: How does ciltacabtagene autoleucel differ from other CAR-T therapies in multiple myeloma?
A: It targets BCMA with a tandem single-domain antibody, potentially enhancing binding affinity and efficacy compared to single-target CAR-Ts.

Q2: What are the main safety considerations?
A: Cytokine release syndrome occurs in most patients but is usually manageable. Neurotoxicity rates are lower than in some other CAR-Ts.

Q3: Is there data supporting use outside relapsed/refractory settings?
A: Ongoing trials, such as CARTITUDE-5, are evaluating earlier lines of therapy, aiming for approval in these settings.

Q4: What are the barriers to market expansion?
A: Manufacturing complexities, high treatment costs, and regulatory approval timelines limit rapid expansion.

Q5: How does the pricing compare to competitors?
A: Similar to other CAR-T therapies, with a price around $410,000 per course; value proposition depends on durability and response rates.

---

References

1. [1] National Cancer Institute. (2022). Ciltacabtagene autoleucel (Carvykti) for Multiple Myeloma.
2. [2] U.S. Food and Drug Administration. (2022). FDA approves ciltacabtagene autoleucel for multiple myeloma.
3. [3] MarketWatch. (2023). CAR-T therapy market size and forecast.
4. [4] Janssen. (2022). Carvykti (ciltacabtagene autoleucel) prescribing information.
5. [5] GlobalData. (2023). Multiple myeloma CAR-T therapy pipeline analysis.